Tesamorelin

Overview

Tesamorelin is a synthetic analog of growth hormone releasing hormone, built on the full natural sequence and then modified to resist the enzyme that would normally break it down quickly. That single modification is what gives it staying power, and it is part of why Tesamorelin has one of the most complete research records in this category. It is also distinctive in being an FDA approved medication, studied and approved for a specific medical condition, which means its data comes from formal randomized clinical trials rather than smaller studies. Within the catalog it is presented strictly as a research compound. It sits in the growth hormone axis category.

How it works

Tesamorelin acts on the growth hormone releasing hormone receptor in the pituitary gland to restore the body’s own pulsatile release of growth hormone, rather than supplying growth hormone from outside, which keeps the natural feedback system intact. The key to its design is a chemical group added to one end of the molecule that shields it from an enzyme called DPP4, which would otherwise degrade the natural hormone within minutes. By resisting that breakdown, Tesamorelin produces a more durable signal, and the resulting growth hormone pulse is studied for its downstream effects on metabolism. Researchers note that prompting the body’s own release this way avoids some of the issues seen when growth hormone is given directly, which can disrupt the body’s normal regulation.

What researchers study

In randomized, placebo controlled clinical trials, Tesamorelin has been studied most thoroughly for reducing visceral adipose tissue, the deep abdominal fat that wraps around the organs and is most closely tied to metabolic risk, while preserving lean mass. The effect in these trials was concentrated in the visceral compartment specifically, rather than acting as a general fat loss approach, which is part of what makes the data distinctive. Researchers have since explored the same growth hormone pathway in other metabolic settings beyond its approved use. Because it cleared the bar of formal trials, it carries one of the cleaner safety and efficacy datasets in the peptide field. As with the rest of the catalog, it is presented here only as a research compound.

Published references

• Reduction in Visceral Adiposity Is Associated With an Improved Metabolic Profile in Patients Receiving Tesamorelin
• Growth Hormone and Tesamorelin in the Management of HIV-Associated Lipodystrophy

Research Use Only. Not for human or animal use.